RxDoctor Payments DataLook up a doctor →

Frances Murray, MD

Family Medicine · Bridgeport, WVNPI 1043262942

Payments from drug & device makers

$10,340in general payments, 2019–2025

Across 704 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • Astellas Pharma US Inc$816
  • AstraZeneca$787
  • Lilly USA, LLC$496
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$10,24699%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,340 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$122,879
Medicare patients
238
Services billed
5,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$61,956
TrulicityDulaglutide26$60,039
JanuviaSitagliptin Phosphate26$39,537
JardianceEmpagliflozin24$37,237
XareltoRivaroxaban22$33,888
OzempicSemaglutide12$30,410
EliquisApixaban16$29,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$21,539
FarxigaDapagliflozin Propanediol12$18,255
SynthroidLevothyroxine Sodium156$17,853
TradjentaLinagliptin13$16,561
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$9,803
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,501
Rosuvastatin Calcium309$5,178
Novolog FlexpenInsulin Aspart14$3,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$496$121,99464 claims
Boehringer IngelheimJardiance, Tradjenta$327$53,79837 claims
MerckJanuvia$150$39,53726 claims
Johnson & JohnsonXarelto$175$33,88822 claims
Novo NordiskOzempic$1,423$30,41012 claims
PfizerEliquis$445$29,19216 claims
GSKTrelegy Ellipta$210$21,53912 claims
AstraZenecaFarxiga$787$18,25512 claims
AbbVieSynthroid$1,814$17,853156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →